N-[4-(2-chloroethoxy)-2-nitrophenyl]acetamide | 672961-06-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-(2-chloroethoxy)-2-nitrophenyl]acetamide
• 英文别名: N-[2-nitro-4-(2-chloroethoxy)phenyl]-acetamide
• CAS: 672961-06-7
• 化学式: C₁₀H₁₁ClN₂O₄
• 分子量: 258.661
• InChiKey: JSFDICHNIQWCSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[4-(2-chloroethoxy)-2-nitrophenyl]acetamide 在 盐酸 、 Ra-Ni 、 potassium carbonate 、 一水合肼 、 potassium iodide 作用下， 以 乙醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 29.0h， 生成 4-[2-(4-(3-三氟甲基苯基)哌嗪-1-基)-乙氧基]-苯-1,2-二胺
  参考文献：
  名称：

  Synthesis, dopamine D2 receptor binding studies and docking analysis of 5-[3-(4-arylpiperazin-1-yl)propyl]-1H-benzimidazole, 5-[2-(4-arylpiperazin-1-yl)ethoxy]-1H-benzimidazole and their analogs

  摘要：

  5-[3-(4-Arylpiperazin-1-yl)propyl]-1H-benzimidazoles and 5-[2-(4-aryipiperazin-1-yl)ethoxy]-1H-benzimidazoles were synthesized and their affinity for the D-1, D-2 and 5-HT1A, receptors examined. They expressed a rather high affinity for the D-2 doparnine receptor. The main features of ligand-D-2 receptor interactions revealed by docking analyses were: salt bridge between piperazine ring protonated N-1 and Asp 86, hydrogen bonds of ligand bezimidazole part with Ser 141, Ser 122 and His 189, edge-to-face interactions of arylpiperazine aromatic ring with Phe 178, Tyr 216 and Trp 182 and hydrogen bond between ethereal oxygen in ethylenoxy ligands and hydrogen of Phe 185 or Trp 115. The most active 5-{2-[4-(2-methoxyphenyl)-piperazin-1-yl]ethoxy}-1,3-di hydro-2H-benzimidazole-2-thione (27) has a maximal number of attractive interactions. A satisfactory correlation between docking of the compounds into the D-2 receptor and competition binding results was observed. (c) 2005 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2004.10.006
• 作为产物：
  描述：

  2-氯乙基 4-硝基苯基醚 在 硝酸 、 溶剂黄146 、 锌 作用下， 反应 7.0h， 生成 N-[4-(2-chloroethoxy)-2-nitrophenyl]acetamide
  参考文献：
  名称：

  Synthesis, dopamine D2 receptor binding studies and docking analysis of 5-[3-(4-arylpiperazin-1-yl)propyl]-1H-benzimidazole, 5-[2-(4-arylpiperazin-1-yl)ethoxy]-1H-benzimidazole and their analogs

  摘要：

  5-[3-(4-Arylpiperazin-1-yl)propyl]-1H-benzimidazoles and 5-[2-(4-aryipiperazin-1-yl)ethoxy]-1H-benzimidazoles were synthesized and their affinity for the D-1, D-2 and 5-HT1A, receptors examined. They expressed a rather high affinity for the D-2 doparnine receptor. The main features of ligand-D-2 receptor interactions revealed by docking analyses were: salt bridge between piperazine ring protonated N-1 and Asp 86, hydrogen bonds of ligand bezimidazole part with Ser 141, Ser 122 and His 189, edge-to-face interactions of arylpiperazine aromatic ring with Phe 178, Tyr 216 and Trp 182 and hydrogen bond between ethereal oxygen in ethylenoxy ligands and hydrogen of Phe 185 or Trp 115. The most active 5-{2-[4-(2-methoxyphenyl)-piperazin-1-yl]ethoxy}-1,3-di hydro-2H-benzimidazole-2-thione (27) has a maximal number of attractive interactions. A satisfactory correlation between docking of the compounds into the D-2 receptor and competition binding results was observed. (c) 2005 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2004.10.006

文献信息

• [EN] ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS<br/>[FR] DERIVES D'ARYLGLYCINE UTILISABLES COMME INHIBITEURS DE TRANSPORT DE GLYCINE
  申请人：NPS ALLELIX CORP

  公开号：WO2004022534A1

  公开（公告）日：2004-03-18

  The present invention relates to compounds of Formula (I) and salts solvates and hydrates thereof. The invention further relates to pharmaceutical compositions containing said compounds and methods of treating neurological and neuropsychistric disorders using said compounds.

  本发明涉及式(I)的化合物及其盐、溶剂化物和水合物。该发明进一步涉及含有所述化合物的药物组合物，以及使用所述化合物治疗神经和神经精神障碍的方法。
• [DE] NEUE VERBINDUNGEN MIT DOPAMINERGER UND/ODER SEROTONINERGER AKTIVITÄT<br/>[EN] NOVEL COMPOUNDS HAVING A DOPAMINERGIC AND/OR SEROTONINERGIC ACTIVITY<br/>[FR] NOUVEAUX COMPOSES A ACTIVITE DOPAMINERGIQUE ET/OU SEROTONINERGIQUE
  申请人：PROTEOSYS AG

  公开号：WO2004035534A3

  公开（公告）日：2004-06-17